[1] Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology, 1996, 23:164-176.
[2] Garcia-Tsao G, Parikh CR, Viola A, et al. Acute kidney injury in cirrhosis. Hepatology, 2008, 6:2064-2077.
[3] Karvellas CJ, Durand F, Nadim MK, et al. Acute kidney injury in cirrhosis. Crit Care Clin, 2015,4:737-750.
[4] Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care, 2004,4:R204-R212.
[5] Mehta RL,Kellum JA,Shah SV,et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit care,2007,2:R31.
[6] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012,4:179-184.
[7] Angeli P, Gines P, Wong F. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascitesq. J Hepatol, 2015,4:968-974.
[8] Englberger L, Suri RM, Li Z, et al. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care, 2011,1:R16.
[9] Luo X, Jiang L, Du B, et al. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Crit Care, 2014,4:R144.
[10] Bagshaw SM, George C, Bellomo R, et al. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant, 2008,5:1569-1574.
[11] Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J, 2007,56:1310-1318.
[12] Luo X, Jiang L, Du B, et al. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Crit Care, 2014, 4:R144.
[13] Ye X, Liu X, Song D, et al. Estimating glomerular filtration rate by serum creatinine or/and cystatin C equations: An analysis of multi-centre Chinese subjects. Nephrology, 2016,5:372-378.
[14] Liao R, Wu H, Yi Y, et al. Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma. J Exp Clin Cancer Res, 2013,22.doi: 10.1186/1756-9966-32-22.
[15] Kjeldsen L, Johnsen AH, Sengelov H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem, 1993,14:10425-10432.
[16] Honore PM, Jacobs R, Joannes-Boyau O, et al. Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at the bedside. Ann Intensive Care,2012,2:24. 1.doi: 10.1186/2110-5820-2-24.
[17] Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol, 2011,22:2301-2309.
[18] Treeprasertsuk S, Wongkarnjana A, Jaruvongvanich V, et al. Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions. BMC Gastroenterol, 2015,15:140. doi: 10.1186/s12876-015-0372-5.
[19] Barreto R, Elia C, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol, 2014,1:35-42.
[20] Gungor G, Ataseven H, Demir A, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int, 2014,1:49-57.
[21] Fagundes C, Pepin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol, 2012,2:267-273.
[22] Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci, 2012,9:2362-2370.
[23] Ichimura T,Bonventre JV,Bailly V,et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, Is up-regulated in renal cells after injury. J Biol Chem,1998,7:4135-4142.
[24] Nogare AL, Veronese FV, Carpio VN, et al. Kidney injury molecule-1 expression in human kidney transplants with interstitial fibrosis and tubular atrophy. BMC Nephrol, 2015,19. doi: 10.1186/s12882-015-0011-y.
[25] Nan-ya K, Kajihara M, Kojima N, et al. Usefulness of urinary kidney injury molecule-1 (Kim-1) as a biomarker for cisplatin-induced sub-chronic kidney injury. J Appl Toxicol, 2015,2:124-132.
[26] 吴诗品, 苏冬娜. 外周血KIM-1在肝硬化合并肝肾综合征患者中的表达及意义. 中国实验诊断学, 2015,5. R575.2.
[27] van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol, 2007,2:209-217.
[28] Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol, 2010,5:455-462.
[29] Obermüller N, Geiger H, Weipert C, et al. Current developments in early diagnosis of acute kidney injury. Int Urol Nephrol, 2014,1:1-7.
[30] Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int, 2006,1:199-203. |
